Oct 10 (Reuters) – Bristol-Myers Squibb Co: * BRISTOL MYERS SQUIBB STRENGTHENS AND DIVERSIFIES CELL THERAPY PORTFOLIO WITH ACQUISITION OF ORBITAL THERAPEUTICS * BRISTOL-MYERS SQUIBB CO – BMS TO PAY $1.5 BILLION IN CASH FOR ORBITAL Source text: Further company coverage:
(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)